46 results
8-K/A
EX-99.2
LSTA
Lisata Therapeutics Inc
4 Oct 22
Other Events
4:42pm
labeling, the recall or discontinuation of our products, or additional record-keeping or reporting requirements. If any such changes were
424B3
LSTA
Lisata Therapeutics Inc
29 Jul 22
Prospectus supplement
4:06pm
:
regulatory authorities may withdraw their approval of the product;
regulatory authorities may require a recall of the product or Caladrius may voluntarily … recall a product;
regulatory authorities may require the addition of warnings or contradictions in the product labeling, narrowing of the indication
8-K
EX-10.1
dcq52m9
4 Jun 21
Entry into a Material Definitive Agreement
4:44pm
8-K
EX-10.1
rc4oazbgb43l6 7ot2r
25 Jan 21
Caladrius Biosciences Announces $25.0 Million Private Placement
4:01pm
8-K
EX-10.1
ws00e k4urzvnwu0h
10 Jul 20
Entry into a Material Definitive Agreement
4:41pm
8-K
EX-10.1
vzmms4kh llo5hbi
26 May 20
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
8:02am
8-K
EX-10.1
10wasco c23pnp
24 Apr 20
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:02pm